Description
An oxopurine that is a derivative of xanthine, methylated at N-1 and N-3 and carrying a 1,3-dioxolan-2-ylmethyl group at N-7, used in the treatment of asthma.
Chemical properties
| Chemical formula | Net charge | Average mass |
|---|---|---|
| C11H14N4O4 | 0 | 266.254 |
Nomenclature
| IUPAC | SMILES | InChI | InChIKey | Synonyms |
|---|---|---|---|---|
| 7-(1,3-dioxolan-2-ylmethyl)-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione | N1(C(N(C2=C(C1=O)N(C=N2)CC3OCCO3)C)=O)C | InChI=1S/C11H14N4O4/c1-13-9-8(10(16)14(2)11(13)17)15(6-12-9)5-7-18-3-4-19-7/h6-7H,3-5H2,1-2H3 | HWXIGFIVGWUZAO-UHFFFAOYSA-N |
|
Citations
- Cirillo, R, et al. 1988. Doxofylline, an antiasthmatic drug lacking affinity for adenosine receptors. Archives Internationales De Pharmacodynamie Et De Therapie. 295.
- Dini, FL, et al. 2001. Doxofylline: a new generation xanthine bronchodilator devoid of major cardiovascular adverse effects. Current Medical Research and Opinion. 16(4).
- Keller, AN, et al. 2017. Drugs and drug-like molecules can modulate the function of mucosal-associated invariant T cells. Nature Immunology. 18(4).
- Page, CP, et al. 2010. Doxofylline: a "novofylline". Pulmonary Pharmacology & Therapeutics. 23(4).
- Riffo-Vasquez, Y, et al. 2014. Doxofylline, a novofylline inhibits lung inflammation induced by lipopolysacharide in the mouse. Pulmonary Pharmacology & Therapeutics. 27(2).
- Shukla, D, et al. 2009. Doxofylline: a promising methylxanthine derivative for the treatment of asthma and chronic obstructive pulmonary disease. Expert Opinion On Pharmacotherapy. 10(14).
- Zhang, Y, et al. 2016. Identifying the antiasthmatic target of doxofylline using immobilized β2 -adrenoceptor based high-performance affinity chromatography and site-directed molecular docking. Journal of Molecular Recognition : JMR. 29(10).